Cancer Family
Malignant Endocrine Neoplasm
CI-CAN-00000230Explore in graph →
576 active trials16 approved drugs58 evidence items
- NCIt
- C3575
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000230Explore in graph →
Clinical trials
1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (238)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07472322 | ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 | not yet recruiting | Phase 1 / Phase 2 | 31 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 |
| clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07743138 | STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07819591 | Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC | not yet recruiting | Phase 2 | 47 | Shaodong HongOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial(PEARL RCT) | not yet recruiting | Phase 2 | 46 | University Health Network, TorontoOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07640932 | Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer(LUPINE) | not yet recruiting | Phase 2 | 69 | Yonsei UniversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07798947 | A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC | not yet recruiting | Phase 2 | 120 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07561645 | A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung(ALPINE 2) | not yet recruiting | Phase 2 | 75 | Technische Universität DresdenOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07738159 | Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 92 | West China HospitalOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07712094 | AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer | not yet recruiting | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07698054 | Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer | not yet recruiting | Phase 2 | 130 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07684170 | Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 58 | Compass TherapeuticsINDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07632209 | Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment(Aurora003) | not yet recruiting | Phase 2 | 46 | Yayi HeOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | not yet recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07547332 | Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC | not yet recruiting | Phase 2 | 84 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07538258 | Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer(Aurora004) | not yet recruiting | Phase 2 | 27 | Yayi HeOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07538271 | A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer(Aurora 005) | not yet recruiting | Phase 2 | 33 | Yayi HeOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07501169 | Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)(STAR-01) | not yet recruiting | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07520357 | A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 23 | Beijing GoBroad HospitalOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07510594 | A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07001995 | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 596 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
| NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy | not yet recruiting | Phase 1 / Phase 2 | 48 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07398560 | Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study | not yet recruiting | Phase 2 | 47 | The Third Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06790589 | COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer | not yet recruiting | Phase 2 | 70 | AHS Cancer Control AlbertaOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07388875 | Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC(SKB264-ANLO) | not yet recruiting | Phase 2 | 30 | China Medical University, ChinaOTHER | 0 | Feb 5, 2026 | clinicaltrials |
| NCT07381543 | Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone | not yet recruiting | Phase 2 | 76 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 2 | 31 | China Medical University, ChinaOTHER | 0 | Jan 29, 2026 | clinicaltrials |
| NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | not yet recruiting | Phase 2 | 44 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07337447 | Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)(REWENEC 01) | not yet recruiting | Phase 2 | 122 | Hospices Civils de LyonOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07289048 | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07200154 | Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07156019 | Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07103408 | A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07097948 | Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033(Adjuvant) | not yet recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076095 | A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer | not yet recruiting | Phase 2 | 200 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Jul 21, 2025 | clinicaltrials |
| NCT07069270 | A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy | not yet recruiting | Phase 2 | 28 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 16, 2025 | clinicaltrials |
| NCT07004712 | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer | not yet recruiting | Phase 2 | 46 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06978153 | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 66 | Tang-Du HospitalOTHER | 0 | May 18, 2025 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials